CCG
RXRX icon

Ceeto Capital Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Ceeto Capital Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-52,000
Closed -$275K – 187
2025
Q1 		$275K Sell
52,000
-28,000
-35% -$204K 0.1% 135
2024
Q4 		$541K Hold
80,000
– – 0.2% 100
2024
Q3 		$527K Buy
80,000
+3,000
+4% +$21.5K 0.2% 103
2024
Q2 		$578K Buy
+77,000
New +$672K 0.22% 94

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Ceeto Capital Group's RXRX Position: Q2 2025 in Review

Ceeto Capital Group sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 52,000 shares — an estimated $275K sold.

Ceeto Capital Group first reported a position in RXRX in Q2 2024 and held it in 4 quarters. The position peaked at $578K in Q2 2024. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • Ceeto Capital Group reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Ceeto Capital Group sold 52,000 Recursion Pharmaceuticals shares in Q2 2025, an estimated $275K.
  • Ceeto Capital Group first reported a position in Recursion Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Ceeto Capital Group's Recursion Pharmaceuticals position peaked at $578K in Q2 2024.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Ceeto Capital Group's 13F filing for Q2 2025, filed 14 Aug 2025.